Device innovation for diabetes: factory-direct CGM systems — 14-day wearable sensors with real-time readings, OEM/ODM ready.
Continuous glucose monitoring is the device innovation that changed diabetes care. The Artemisine CGMS pairs a factory-calibrated 14-day wearable sensor with a transmitter and smartphone app, streaming glucose readings every few minutes with high/low alarms — no routine fingerstick calibration required.
For distributors, our CGM is offered factory-direct with OEM/ODM options: private-label app, localized language packs, market-specific packaging and complete technical files (risk analysis, biocompatibility, software verification) for CE-style and national registrations.
For diabetes clinics and national programs, bundling CGM with our injectable insulin and GLP-1 portfolio creates a complete diabetes-care supply chain from a single manufacturer.
All products are GMP manufactured and supplied with COA, COPP, DMF and CTD dossiers. Tap any product for specifications and WHO prescribing guidance.
Tell us your target market and annual volume — our export team replies within 24 hours.
A 14-day factory-calibrated wearable sensor, a reusable transmitter, and a smartphone app with real-time readings, trend arrows, high/low alarms and data sharing for caregivers.
Yes — private-label branding, localized app languages, custom packaging and full technical documentation for your market registration are available.
Yes. Distributors frequently bundle CGMS with our human insulin, insulin glargine and GLP-1 pens to offer complete diabetes management solutions from one factory.
Artemisine Medicines